Sermorelin: Complete Research Guide (2026)

Sermorelin (GRF(1-29)NH2) is one of the most extensively studied Growth Hormone Releasing Hormone (GHRH) analogues in preclinical and clinical research. As a 29-amino-acid synthetic peptide corresponding to the biologically active fragment of endogenous GHRH, Sermorelin has been used since the 1970s as a diagnostic tool for pituitary function and as a research reagent for studying the somatotropic axis. This 2026 guide covers Sermorelin's mechanism of action, molecular characterization, comparison with CJC-1295 and GHRP secretagogues, dosing considerations for preclinical protocols, storage and reconstitution, purity verification, and where to source research-grade material in Europe.

Sermorelin at a glance

Historical context and development

Sermorelin was developed in the late 1970s as researchers sought to isolate and synthesize the active fragment of endogenous GHRH. Native GHRH is a 44-amino-acid peptide first characterized from pancreatic tumor extracts. Subsequent structure-activity studies demonstrated that the first 29 N-terminal amino acids retained full biological activity at the GHRH receptor. This truncated peptide, designated GRF(1-29)NH2 and later given the international non-proprietary name Sermorelin, became the standard research and diagnostic tool for probing pituitary GH reserve.

Between 1997 and 2008, Sermorelin was approved by the FDA (United States) under the brand name Geref for pediatric use in growth hormone deficiency. It was voluntarily withdrawn from that market in 2008 for commercial reasons — not for safety or efficacy concerns. It remains widely available as a research chemical and continues to be used in preclinical models studying the somatotropic axis, pituitary reserve, and GH pulsatility. For research on gastric-repair peptides where the somatotropic axis is a co-variable, Sermorelin is often paired with BPC-157 in study designs.

Mechanism of action

Sermorelin binds to the GHRH receptor (GHRHR), a G-protein coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. Receptor activation triggers intracellular cAMP accumulation via Gs-mediated adenylyl cyclase stimulation. Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates transcription factors including CREB (cAMP Response Element Binding protein). CREB phosphorylation upregulates transcription of the growth hormone gene (GH1) and stimulates release of pre-formed GH from secretory granules into circulation.

A defining feature of Sermorelin's mechanism is that it preserves the natural pulsatile pattern of endogenous GH release. Unlike exogenous administration of recombinant GH (rhGH), which produces sustained supraphysiological levels, Sermorelin-induced GH release remains subject to negative feedback regulation via hypothalamic somatostatin. This preserves physiological rhythm and prevents complete suppression of endogenous GH production — a key research advantage for studying pituitary reserve and pulsatility in preclinical models.

Sermorelin vs CJC-1295 vs GHRPs

Understanding where Sermorelin sits within the broader GH-secretagogue landscape helps researchers choose the right tool for their protocol:

When to choose Sermorelin over CJC-1295: if the research endpoint requires preserving natural GH pulsatility (e.g., studying diurnal rhythm, negative feedback, pituitary reserve in aged models), Sermorelin's short half-life is an advantage, not a disadvantage. CJC-1295 with DAC, by contrast, produces sustained receptor activation that abolishes the natural pulse pattern — useful for other endpoints but not for pulsatility studies.

Synergy with GHRPs: the most common research combination is a GHRH analogue (Sermorelin or CJC-1295) with a GHRP (Ipamorelin or GHRP-2). GHRH analogues act via the GHRHR, GHRPs act via the ghrelin receptor (GHSR-1a). Simultaneous activation of both pathways produces additive or synergistic GH release in preclinical models. Pepspan's pre-formulated CJC-1295 + Ipamorelin blend is the most-researched combination format sold as a co-lyophilized single-vial preparation.

Reconstitution and dosing considerations

Sermorelin ships as a lyophilized white powder. Standard research reconstitution protocol:

1. Bring the vial to room temperature (20-25 °C) before opening. Cold vials risk moisture condensation on the powder.
2. Calculate the diluent volume. For a 5mg vial, adding 2 ml of bacteriostatic water yields 2.5 mg/ml. Adding 5 ml yields 1.0 mg/ml — useful for lower per-dose concentrations.
3. Inject slowly down the inner wall of the vial. Never directly onto the powder — this creates foam and denatures peptide.
4. Swirl gently until fully dissolved (5-10 seconds). Do not shake vigorously.
5. Store immediately at 2-8 °C. Use within 28 days.

Preclinical dosing typically falls between 100-500 mcg per administration, delivered subcutaneously in animal models, once or twice daily. Because of Sermorelin's short native half-life, research protocols often schedule evening administration to align with the natural nocturnal GH release peak. Pepspan does not provide dosing recommendations for human use — Sermorelin is sold strictly under Research Use Only status.

Storage and stability

Lyophilized Sermorelin: store at 4°C for several months, or -20°C for long-term stability (years). Keep away from direct light and repeated freeze-thaw cycles, which cause peptide degradation.

Reconstituted Sermorelin: store at 2-8°C in the refrigerator and use within 28 days. Reconstituted solution left at room temperature degrades within hours due to enzymatic cleavage. Never freeze reconstituted Sermorelin as this causes precipitation and loss of activity.

Purity verification

Research-grade Sermorelin should have a minimum HPLC purity of 98%. Below this threshold, degradation products and truncated peptide fragments can confound research results by producing off-target receptor activity or reduced potency. Pepspan's minimum specification is 98% HPLC; recent production batches consistently exceed 99%.

Every Sermorelin batch sold by Pepspan is independently tested at Janoshik Analytical (Brno, Czechia), a third-party laboratory specialized in peptide analysis. The Certificate of Analysis (COA) includes HPLC purity, mass spectrometry identity confirmation, residual solvents testing, and microbiological screening. The COA is delivered with every order and is downloadable via QR code on the vial. This third-party verification distinguishes Pepspan from competitors that publish only internal manufacturer analyses.

EU regulatory framework

Sermorelin is sold across the EU/EEA as a Research Use Only (RUO) laboratory reagent. It is not authorized as a medicine by the European Medicines Agency (EMA) and cannot be marketed or used for human consumption. No medical prescription is required for research purchase. Buyers must be qualified researchers, laboratory professionals, or work in R&D.

Sermorelin ships without customs friction from Pepspan's European warehouse (Spain + Prague hub) to all 27 EU member states plus EEA countries. Detailed regulatory information: Research peptides legal status in Europe.

Buying Sermorelin at Pepspan

Frequently asked questions

What is Sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide (GRF(1-29)NH2) corresponding to the biologically active fragment of human GHRH. Molecular weight 3,357.9 Da. It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates pulsatile release of endogenous GH. First developed in the 1970s.

How does Sermorelin work?

Binds GHRH receptor (Gs-GPCR) → cAMP-PKA-CREB cascade → transcription of GH1 gene and release of pre-formed GH from secretory granules. Preserves pulsatile pattern via somatostatin negative feedback — unlike exogenous rhGH.

Sermorelin vs CJC-1295?

Both are GHRH analogues. Sermorelin: 10-12 min half-life, preserves natural pulsatility. CJC-1295 (no DAC): ~30 min, modified for enzymatic resistance. CJC-1295 with DAC: 6-8 days, albumin-bound for sustained signaling. Choose Sermorelin for pulsatility research; CJC for extended-exposure studies.

Typical Sermorelin dosing in preclinical research?

100-500 mcg per administration, subcutaneous in animal models, once or twice daily. Reconstitute with bacteriostatic water immediately before use (0.5-2 mg/ml typical). Evening administration aligns with nocturnal GH peak. Pepspan does not provide dosing recommendations for human use — RUO only.

How to store Sermorelin?

Lyophilized: 4°C months / -20°C years. Reconstituted: 2-8°C, use within 28 days. Never freeze reconstituted solution. Away from direct light.

Is Sermorelin legal to buy in Europe?

Yes. Sold legally across EU/EEA as Research Use Only (RUO) laboratory reagent. Not authorized as medicine by EMA. No prescription required for research purchase. Qualified researcher only.

Where to buy Sermorelin in Europe?

Pepspan sells Sermorelin 5mg lyophilized at €34.90/vial, EU stock, Janoshik COA per batch. Ships to all 27 EU/EEA countries no customs. Wholesale 10+ vials = 20% off automatic.

Can Sermorelin be combined with other peptides?

Yes. Most-researched combination is GHRH analogue + GHRP (Sermorelin+Ipamorelin, or CJC-1295+Ipamorelin). Additive/synergistic GH release via dual receptor activation (GHRHR + GHSR-1a). Pepspan sells CJC-1295+Ipamorelin blend co-lyophilized.

What purity should research-grade Sermorelin have?

Minimum 98% HPLC. Below that, degradation products confound results. Pepspan spec >98%, recent batches >99%. Every batch verified by Janoshik Analytical (Brno, Czechia): HPLC purity, MS identity, residual solvents, microbiological screening. COA per order.